Abstract
The occurrence of autoantibodies is a common feature of autoimmune diseases. This review is intended to give an overview of the most important autoantibodies and their role in diagnosis, disease activity and prognosis in rheumatoid arthritis (RA), systemic lupus erythematodes (SLE) and multiple sclerosis (MS). Whereas in RA and SLE these antibodies are meaningful for diagnosis and partially for the prognosis of the disease, the situation is quite different in the case of MS. Up to date, no specific antibody is known to be exclusively present in the serum or cerebrospinal fluid (CSF) of MS-patients compared to the respective fluids of healthy individuals. Nevertheless, there are some antigens that are reported to be bound significantly more often by MS-patients serum or CSF than by comparable samples of healthy volunteers. In addition to the importance of several autoantibodies for diagnosis of the respective disease, the serum concentration of certain antibodies in RA and SLE is associated with therapy response. Since therapy with biologicals (e.g. TNF- αblockade, B-cell depletion) is expensive, monitoring these autoantibodies seems to be an additional useful tool for early identification of therapy responders or non-responders.
Keywords: Autoantibodies, rheumatoid arthritis, systemic lupus erythematodes, diagnosis, prognosis, therapy
Current Pharmaceutical Design
Title: Autoantibodies in Autoimmune Diseases
Volume: 16 Issue: 14
Author(s): M. Eggert, U. K. Zettl and G. Neeck
Affiliation:
Keywords: Autoantibodies, rheumatoid arthritis, systemic lupus erythematodes, diagnosis, prognosis, therapy
Abstract: The occurrence of autoantibodies is a common feature of autoimmune diseases. This review is intended to give an overview of the most important autoantibodies and their role in diagnosis, disease activity and prognosis in rheumatoid arthritis (RA), systemic lupus erythematodes (SLE) and multiple sclerosis (MS). Whereas in RA and SLE these antibodies are meaningful for diagnosis and partially for the prognosis of the disease, the situation is quite different in the case of MS. Up to date, no specific antibody is known to be exclusively present in the serum or cerebrospinal fluid (CSF) of MS-patients compared to the respective fluids of healthy individuals. Nevertheless, there are some antigens that are reported to be bound significantly more often by MS-patients serum or CSF than by comparable samples of healthy volunteers. In addition to the importance of several autoantibodies for diagnosis of the respective disease, the serum concentration of certain antibodies in RA and SLE is associated with therapy response. Since therapy with biologicals (e.g. TNF- αblockade, B-cell depletion) is expensive, monitoring these autoantibodies seems to be an additional useful tool for early identification of therapy responders or non-responders.
Export Options
About this article
Cite this article as:
Eggert M., Zettl U. K. and Neeck G., Autoantibodies in Autoimmune Diseases, Current Pharmaceutical Design 2010; 16 (14) . https://dx.doi.org/10.2174/138161210791164144
DOI https://dx.doi.org/10.2174/138161210791164144 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Gene Expression Profiles in Human Autoimmune Disease
Current Pharmaceutical Design Enzyme Inhibition as a Key Target for the Development of Novel Metal-Based Anti-Cancer Therapeutics
Anti-Cancer Agents in Medicinal Chemistry Advances in Exploring the Role of Micrornas in Inflammatory Bowel Disease
MicroRNA Paracetamol (Acetaminophen) Efficacy and Safety in the Newborn
Current Drug Metabolism RING-, HECT-, and RBR-type E3 Ubiquitin Ligases: Involvement in Human Cancer
Current Cancer Drug Targets Heme Oxygenase-1 as a Target for the Design of Gene and Pharmaceutical Therapies for Autoimmune Diseases
Current Gene Therapy Chronic Streptococcal and Non-Streptococcal Pharyngitis
Infectious Disorders - Drug Targets Application of Stem Cell Therapy During the Treatment of HIV/AIDS and Duchenne Muscular Dystrophy
Current Stem Cell Research & Therapy Nanoparticle Delivery of Transition-Metal Chelators to the Brain: Oxidative Stress will Never See it Coming!
CNS & Neurological Disorders - Drug Targets Antibody Fragments as Potential Biopharmaceuticals for Cancer Therapy: Success and Limitations
Current Medicinal Chemistry Extracellular Vesicles as Drug Delivery Vehicles for Rheumatoid Arthritis
Current Stem Cell Research & Therapy Diagnostic Utility of Anti-Cyclic Citrullinated Peptide and Anti-Modified Citrullinated Vimentin Antibodies in Rheumatoid Arthritis
Protein & Peptide Letters Subtype Selectivity in Phosphodiesterase 4 (PDE4): A Bottleneck in Rational Drug Design
Current Pharmaceutical Design Identification of SER-PRO-CYS Peptide in Blood Serum of Multiple Sclerosis Patients
Protein & Peptide Letters Insights on the Neuromodulatory Propensity of Selaginella (Sanjeevani) and its Potential Pharmacological Applications
CNS & Neurological Disorders - Drug Targets Drug-Induced Anemia and Other Red Cell Disorders: A Guide in the Age of Polypharmacy
Current Clinical Pharmacology Clinical Pharmacokinetics of Ibuprofen Arginine
Current Clinical Pharmacology Von Willebrand Factor and Cardiovascular Disease: From a Biochemical Marker to an Attractive Therapeutic Target
Current Vascular Pharmacology VEGF Signal System: The Application of Antiangiogenesis
Current Medicinal Chemistry Pharmacological Targets for the Inhibition of Neurogenic Inflammation
Current Medicinal Chemistry - Anti-Inflammatory & Anti-Allergy Agents